Legacy Trust’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$682K Buy
7,409
+104
+1% +$9.24K 0.11% 121
2026
Q2
$661K Buy
7,305
+30
+0.4% +$2.51K 0.12% 113
2026
Q1
$583K Sell
7,275
-7,449
-51% -$614K 0.11% 119
2025
Q4
$1.26M Sell
14,724
-20
-0.1% -$1.64K 0.23% 75
2025
Q3
$1.15M Sell
14,744
-240
-2% -$18.8K 0.23% 75
2025
Q2
$1.17M Sell
14,984
-22
-0.1% -$1.64K 0.29% 68
2025
Q1
$1.09M Sell
15,006
-92
-0.6% -$6.58K 0.26% 68
2024
Q4
$1.12M Sell
15,098
-3
-0% -$210 0.26% 69
2024
Q3
$997K Sell
15,101
-923
-6% -$67.1K 0.23% 75
2024
Q2
$1.48M Sell
16,024
-75
-0.5% -$6.64K 0.37% 66
2024
Q1
$1.54M Sell
16,099
-38
-0.2% -$3.19K 0.38% 65
2023
Q4
$1.23M Buy
16,137
+39
+0.2% +$2.71K 0.32% 71
2023
Q3
$1.12M Sell
16,098
-207
-1% -$16.6K 0.32% 71
2023
Q2
$1.54M Buy
16,305
+6
+0% +$521 0.42% 67
2023
Q1
$1.35M Sell
16,299
-299
-2% -$23.5K 0.4% 68
2022
Q4
$1.24M Buy
+16,598
New +$1.28M 0.38% 67

Other funds holding EW

Legacy Trust's EW Position: Q3 2026 in Review

Legacy Trust increased its Edwards Lifesciences (EW) stake by 1.4% in Q3 2026, buying an estimated $9.24K and bringing the position to 7,409 shares worth $682K. The position accounts for 0.11% of the portfolio, ranked #121.

Legacy Trust first reported a position in EW in Q4 2022 and has held it in 16 quarters since. The position peaked at $1.54M in Q1 2024. 774 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Legacy Trust held 7,409 shares of Edwards Lifesciences worth $682K as of Q3 2026.
  • Legacy Trust bought 104 Edwards Lifesciences shares in Q3 2026, an estimated $9.24K.
  • Edwards Lifesciences made up 0.11% of Legacy Trust's portfolio in Q3 2026, its #121 holding.
  • Legacy Trust first reported a position in Edwards Lifesciences in Q4 2022 and has held it in 16 quarters since.
  • Legacy Trust's Edwards Lifesciences position peaked at $1.54M in Q1 2024.
  • 774 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Legacy Trust's 13F filing for Q3 2026, filed 6 Nov 2026.